In this episode, we discuss the diagnosis and management of primary myelofibrosis with Dr. Ayalew Tefferi at Mayo Clinic, Rochester, Minnesota. Here are the show notes, including key studies discussed in this episode:1. Risk stratification of PMF: MIPSS70 Score: http://www.mipss70score.ithttps://ascopubs.org/doi/full/10.1200/JCO.2017.76.4886Genetically inspired prognostic scoring system (GIPSS):https://www.nature.com/articles/s41375-018-0107-zType 1 CALR mutation: https://ashpublications.org/blood/article/124/15/2465/33454MYSEC-PM:http://www.mysec-pm.euhttps://www.nature.com/articles/leu20171692. Treatment of PMF with JAK inhibitors https://pubmed.ncbi.nlm.nih.gov/36680511/Momelotinib: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02036-0/fulltextPacritinib : https://ashpublications.org/blood/article/140/Supplement%201/1518/490663https://jamanetwork.com/journals/jamaoncology/fullarticle/2674384Fedratinib:https://onlinelibrary.wiley.com/doi/10.1111/bjh.182843. Allogeneic Transplant in PMFhttps://ashpublications.org/hematology/article/2021/1/453/482995Black African-American patients with primary myelofibrosishttps://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2022009611/4944604. Imtelestat in PMFhttps://www.nejm.org/doi/full/10.1056/NEJMoa1310523

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related